Cardiol Clin. 2022 Aug;40(3):337-344. doi: 10.1016/j.ccl.2022.03.008. Epub 2022 Mar 29.
ABSTRACT
COVID-19 infection triggers a heightened inflammatory response which in turn, increases thrombosis and thromboembolism. Microvascular thrombosis has been detected in various tissue beds which may account for some of the multi-system organ dysfunction associated with COVID-19. Additional research is needed to understand which prophylactic and therapeutic drug regimens are best for the prevention and treatment of thrombotic complications of COVID-19.
PMID:35851457 | PMC:PMC8960156 | DOI:10.1016/j.ccl.2022.03.008